An arrhythmia is a problem with the speed or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. A heartbeat that is too fast is called tachycardia. A heartbeat that is too slow is called bradycardia. Most arrhythmias are harmless, but some can be serious or even life threatening. When the heart rate is too slow, too fast, or irregular, the heart may not be able to pump enough blood to the body. Lack of blood flow can damage the brain, heart, and other organs.
A team of scientists led by Johns Hopkins cardiologist and biomedical engineer Hiroshi Ashikaga, M.D., Ph.D., has developed a mathematical model to measure and digitally map the beat-sustaining electrical flow between heart cells.
Jianmin Cui, PhD, has received a nearly $1.7 million grant from the National Institutes of Health to study the molecular bases for the function of potassium channels vital for the heart, brain, inner ear and other tissues.
Scientists from Cardiff and Swansea Universities are combining the principles of the butterfly effect and computer simulation to explore new ways of predicting and controlling the beginnings of heart disease.
iRhythm Technologies, Inc., a leading digital health care solutions company focusing on the advancement of cardiac care, presented study results that demonstrate high compliance among patients using long term electrocardiogram (ECG) patch monitors to detect atrial fibrillation (AFib).
Case Western Reserve's chemical compound aimed at restoring spinal cord function may have an additional purpose: stopping potentially fatal arrhythmias after heart attack.
Fewer patients undergoing aortic valve replacement (AVR) are being re-hospitalized in the year following surgery, indicating the surgery is safer and the recovery has become easier, according to an article in the February 2015 issue of The Annals of Thoracic Surgery.
Video-assisted thoracoscopic surgery lobectomy offers better short-term outcomes for patients with early-stage non-small-cell lung cancer than open lobectomy, multi-institutional research confirms.
Evidence already exists for the beneficial effects of drinking moderate amounts of alcohol on the risk of developing a number of heart conditions; however, the role it plays in the risk of developing heart failure has been under-researched with conflicting results.
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration has approved SAVAYSA (edoxaban) Tablets, an oral, once-daily selective factor Xa-inhibitor, to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF).
At Galway Hospital, in Ireland, a device is currently used to "predict" cardiac events in people at risk of sudden cardiac death.
Patients suffering from the world's most common heart rhythm disorder can have their long-term outcomes significantly improved with an aggressive management of their underlying cardiac risk factors, according to University of Adelaide researchers.
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has launched a new formulation of LIXIANA 60 mg Tablets (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban, approval to market: September 26, 2014; NHI drug price listing: November 25, 2014) in Japan for the recently approved indications: the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and the treatment and recurrence prevention of venous thromboembolism (VTE) [deep vein thrombosis (DVT) and pulmonary thromboembolism (PE)].
Groundbreaking findings describing the link between cardiac abnormalities and sudden unexpected death in epilepsy (SUDEP) will be presented at the American Epilepsy Society's Annual Meeting in December.
Jessica Zègre-Hemsey, a cardiac monitoring expert at the University of North Carolina at Chapel Hill, and her colleagues at the University of California San Francisco, revealed more than 2.5 million alarms were triggered on bedside monitors in a single month - the first figure ever reported from a real-world hospital setting.
Digoxin, a drug commonly used to treat heart conditions, was associated with a 71 percent higher risk of death and a 63 percent higher risk of hospitalization among adults with diagnosed atrial fibrillation and no evidence of heart failure, according to a Kaiser Permanente study that appears in the current online issue of Circulation: Arrhythmia and Electrophysiology.
Black patients who have been diagnosed with heart failure are no less likely than white patients to get atrial fibrillation (an irregular heartbeat, or arrhythmia), according to a new study led by researchers in the Perelman School of Medicine at the University of Pennsylvania, which was presented today at the 2014 Scientific Sessions of the American Heart Association.
iRhythm Technologies, Inc. announced today that study results presented during the American Heart Association Scientific Sessions showed an association between a high burden of atrial fibrillation (AFib) and lower cognitive function, specifically executive and verbal function.
Cardiome Pharma Corp. today announced results from a Phase 3 clinical study conducted with BRINAVESS (vernakalant intravenous, RSD 1235) in the Asia-Pacific (A-P) region.
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee voted 9 to 1 to recommend approval of once-daily SAVAYSA (edoxaban) 60 mg dosing regimen for the reduction in risk of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF).
Nearly 1.8 million people in Germany suffer from atrial fibrillation. This is the most common and clinically significant form of heart rhythm disorder. Shortness of breath, a sudden sense of dizziness, a feeling of pressure in the chest, and palpitations or thumping of the heart so extreme it can be felt beating rapidly and irregularly - this is how many patients describe their first episode of atrial fibrillation.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.